• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Creso Pharma Share Price Moves Up 10% on Record Start (ASX:CPH)

Like 0

By Carl Wittkopp, Tuesday, 19 January 2021

At time of writing the Creso Pharma Ltd [ASX:CPH] share price is trading at 24.2 cents, up 10%. Creso Pharma recently announced a record start for financial year 2021. Creso Pharma is a medicinal cannabis company that brings pharmaceutical...

At time of writing the Creso Pharma Ltd [ASX:CPH] share price is trading at 24.2 cents, up 10%.

ASX Creso Pharma Share Price Chart

Source: Optuma

Where is the growth coming from?

Creso Pharma is a medicinal cannabis company that brings pharmaceutical expertise and methodological rigour to the world of cannabis.

They provide products for both people and animals.

In a recent announcement the company outlined its growing revenue and fantastic start for FY2021:

  • Secured a new purchase order for its leading range of animal health products anibidiol®, from existing commercial partner Virbac Switzerland (AU$247,826).
  • Witnessing strong demand for its products through Latin America — the company secured regulatory approval for its animal health product line from the Ministry of Agriculture and Animal Feed in Uruguay.
  • And in January 2021 the company also finalised delivery of its second purchase order (valued at AU$318,841) for its cannaQIX® products from the South African subsidiary of Lupin International.

The new purchase orders combined with already existing orders brings the total order amount for the company up to AU$1,055,072.

Discover our top three ASX-listed pot stocks in 2021. Click here to learn more.

Creso Pharma recently announced a record start for financial year 2021.

Cresco Pharma and the future of cannabis

The cannabis industry is in hypergrowth mode internationally.

With the market expected to be worth $97.35 billion by the end of 2026.

For Cresco this gives a huge area to expand into both in Australia and overseas.

Let’s take a look at the chart:

ASX CPH Share Price Chart

Source: Optuma

The price fell back from the high in early December into a sideways movement.

With announcements being made regarding the great start to the year, the share price moved up 10% at the time of writing to trade at 24.2 cents.

If the move up continues, then the levels of 28 and 32 cents may provide future resistance.

Should the price happen to fall back, then the level of 21 cents may provide future support.

The global cannabis industry is expanding at an extreme pace as most countries relax their laws towards the plant.

For companies like CPH the future looks bright.

For those thinking of trading Creso Pharma you may be looking for an uptrend to develop before putting your money in, as the current sideways movement may whip you in and out of trades.

CPH is one for a watchlist.

Regards,

Carl Wittkopp,
For Money Morning

PS: Aussie cannabis boom — discover why the Aussie cannabis market is ready again for long-term growth and how you can capitalise. Click here to learn more.

 

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Carl Wittkopp

Carl’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • From geek to God: the trillion dollar maven
    By Callum Newman

    Here’s a few things I discovered this month after reading The Thinking Machine: Jensen Huang, Nvidia, and the World’s Most Coveted Microchip. If you want to be a billionaire, have a read of this!

  • The stock market prices in peace in the Middle East
    By Brian Chu

    Will the conflict between Israel and Iran escalate? Today, I present my views on why it could de-escalate sooner than many are made to believe.

  • Ignore the bores and the bears: some shares are going gangbusters
    By Callum Newman

    All year you and I have been on a mission. It’s to discover if now is the time to be upping your exposure to risk assets, or dialling it down. I put my stake in the ground ages ago: get bullish! It’s working.

Primary Sidebar

Latest Articles

  • From geek to God: the trillion dollar maven
  • The stock market prices in peace in the Middle East
  • Ignore the bores and the bears: some shares are going gangbusters
  • The Perfect Marriage: Combining Fundamental AND Technical Analysis
  • Your best chance to be in the top 10% will come from here

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988